Related Experiment Video

Updated: Feb 11, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K

Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status

Chinedum Eleazu1, Ayogu Charles1, Kate Eleazu2

  • 1Federal University, Ndufu-Alike, Ikwo, Ebonyi State, Nigeria.

Chemico-Biological Interactions
|April 29, 2018
PubMed

Insights

The rising incidence of type 2 diabetes mellitus (T2DM) necessitates novel treatments. Research focuses on Free Fatty Acid Receptor 1 (FFAR1) agonists for safer, glucose-dependent insulin secretion enhancement.

Area of Science:

  • Endocrinology and Pharmacology
  • Molecular and Cellular Biology

Background:

  • Type 2 Diabetes Mellitus (T2DM) incidence is increasing globally.
  • Existing oral T2DM treatments can cause adverse side effects.
  • There is a critical need for novel therapeutic strategies with improved safety profiles.

Purpose of the Study:

  • To review the current status of novel Free Fatty Acid Receptor 1 (FFAR1) agonists development.
  • To highlight FFAR1 as a promising therapeutic target for T2DM management.
  • To discuss the potential of FFAR1 agonists in improving T2DM treatment efficacy and safety.

Main Methods:

  • Literature review of recent research on FFAR1 agonists.
  • Analysis of FFAR1's role in glucose-dependent insulin secretion.
  • Evaluation of the antidiabetic potential and side effect profiles of FFAR1 agonists.

Main Results:

  • FFAR1 (GPR40) is a G-protein coupled receptor expressed in pancreatic β-cells.
  • FFAR1 activation by fatty acids enhances glucose-dependent insulin secretion.
  • Numerous FFAR1 agonists are under investigation for T2DM treatment.

Conclusions:

  • FFAR1 agonists represent a promising therapeutic avenue for T2DM.
  • The glucose-dependent mechanism of FFAR1 offers potential for reduced hypoglycemia risk.
  • Continued development of FFAR1 agonists may lead to safer and more effective T2DM therapies.
Keywords:
AgonistsFatty acidsG protein-coupled receptorInsulin secretionType 2 diabetes mellitus

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.3K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.2K
Types of Receptors: Internal Receptors01:07

Types of Receptors: Internal Receptors

Many cellular signals are hydrophilic and cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind intracellular receptors that reside within the cell cytoplasm or nucleus. Many mammalian steroid hormones and nitric oxide (NO) gas use this cell signaling mechanism.
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
32.7K
Acidity of 1-Alkynes02:42

Acidity of 1-Alkynes


The acidic strength of hydrocarbons follows the order: Alkynes > Alkenes > Alkanes. The strength of an acid is commonly expressed in units of pKa — the lower the pKa, the stronger the acid. Among the hydrocarbons, terminal alkynes have lower pKa values and are, therefore, more acidic. For example, the pKa values for ethane, ethene, and acetylene are 51, 44, and 25, respectively, as shown here.
11.3K
Predicting Products: SN1 vs. SN202:27

Predicting Products: SN1 vs. SN2

Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
17.4K